Stock listing
AMLX Stock Price, News, Filings & Events — Amylyx Pharmaceuticals, Inc.
Selected listing: AMLX · NASDAQ · USD · US
This page tracks Amylyx Pharmaceuticals, Inc.'s AMLX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AMLX:NASDAQ. AMLX:NASDAQ is the stock-level entry point for investors researching Amylyx Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Amylyx Pharmaceuticals, Inc. is a public company traded under the ticker AMLX in the American market. The company has a market capitalization of approximately $1.97 billion. Amylyx focuses on developing innovative therapies for neurological diseases.
- Ticker
- AMLX:NASDAQ
- Asset type
- Stock
- Market cap
- $4.36B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Amylyx Pharmaceuticals, Inc. AMLX:NASDAQ stock context
This page tracks Amylyx Pharmaceuticals, Inc.'s AMLX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AMLX:NASDAQ. AMLX:NASDAQ is the stock-level entry point for investors researching Amylyx Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Amylyx Pharmaceuticals, Inc. is a public company traded under the ticker AMLX in the American market. The company has a market capitalization of approximately $1.97 billion. Amylyx focuses on developing innovative therapies for neurological diseases.
Latest news from Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
August 19, 2026
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
August 18, 2026
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
August 18, 2026
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia o...
August 17, 2026
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
August 3, 2026
Amylyx Pharmaceuticals, Inc. earnings calls
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call
August 6, 2026 · Replay with transcript and chapters
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call
May 7, 2026 · Replay with transcript and chapters
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call
March 3, 2026 · Replay with transcript and chapters
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call
November 6, 2025 · Replay with transcript and chapters
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call
August 7, 2025 · Replay with transcript and chapters
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call
May 8, 2025 · Replay with transcript and chapters
Research Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. investor report
Review AI stock analysis and investor report context for AMLX:NASDAQ.
Amylyx Pharmaceuticals, Inc. company profile
View the public company page for Amylyx Pharmaceuticals, Inc. on 6ix.
Amylyx Pharmaceuticals, Inc. news
Read company news and market updates connected to Amylyx Pharmaceuticals, Inc..
Amylyx Pharmaceuticals, Inc. investor events
Find investor webinars, events, and replay context for Amylyx Pharmaceuticals, Inc..